What is TAP?
TAP is a strategic venture philanthropy funding initiative to accelerate high-risk, innovative blood cancer therapeutics and change the standard of care in leukemia, lymphoma, and multiple myeloma.
Since its establishment in 2007, TAP has invested more than $120 million in over 60 projects.
Since 2017, three TAP-supported therapies have been approved by the U.S. Food and Drug Administration (FDA):
- CPX-351 (Vyxeos®), first approved treatment (an innovative reformulation of two chemotherapies) for patients with certain types of high-risk acute myeloid leukemia (AML)1
- Axicabtagene ciloleucel (Yescarta®), first CAR T-cell immunotherapy approved for patients with non-Hodgkin lymphoma (NHL) and transformed follicular lymphoma (tFL)2
- Tagraxofusp-erzs (Elzonris®), first approved therapy for children and adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN)3
Currently, there are more than 20 LLS-supported assets or companies in clinical development including 5 ongoing or planned registration-enabling studies (click here for portfolio).
Download a presentation that describes more about TAP.
